Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 12:43PM ET
0.2000
Dollar change
+0.0095
Percentage change
4.99
%
Index- P/E- EPS (ttm)-1.05 Insider Own3.24% Shs Outstand20.39M Perf Week3.09%
Market Cap4.08M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float19.73M Perf Month-7.79%
Income-8.18M PEG- EPS next Q- Inst Own5.94% Short Float2.16% Perf Quarter-30.31%
Sales0.00M P/S- EPS this Y- Inst Trans-9.54% Short Ratio0.54 Perf Half Y-52.38%
Book/sh1.53 P/B0.13 EPS next Y- ROA-1.88% Short Interest0.43M Perf Year-75.62%
Cash/sh1.56 P/C0.13 EPS next 5Y- ROE-2.10% 52W Range0.14 - 1.88 Perf YTD-26.44%
Dividend Est.- P/FCF- EPS past 5Y18.59% ROI-30.60% 52W High-89.36% Beta1.58
Dividend TTM- Quick Ratio17.79 Sales past 5Y0.00% Gross Margin- 52W Low41.74% ATR (14)0.02
Dividend Ex-Date- Current Ratio17.79 EPS Y/Y TTM49.16% Oper. Margin0.00% RSI (14)52.06 Volatility12.96% 11.86%
Employees5 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price14.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q92.20% Payout- Rel Volume0.14 Prev Close0.19
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume791.96K Price0.20
SMA204.53% SMA502.00% SMA200-50.97% Trades Volume57,314 Change4.99%
Dec-19-23 09:00AM
Dec-06-23 09:00AM
Nov-02-23 09:00AM
Sep-26-23 09:00AM
Sep-07-23 09:00AM
09:00AM Loading…
Jul-19-23 09:00AM
Jul-13-23 09:00AM
Mar-07-23 09:00AM
Dec-16-22 09:00AM
Nov-18-22 09:00AM
Oct-19-22 09:00AM
Sep-28-22 11:50AM
Aug-12-22 09:00AM
Jul-26-22 09:15AM
Jul-21-22 09:15AM
09:15AM Loading…
Jul-20-22 09:15AM
May-17-22 09:15AM
Apr-19-22 09:15AM
Apr-05-22 09:15AM
Mar-29-22 09:15AM
Mar-22-22 09:15AM
Mar-15-22 09:15AM
Feb-23-22 09:15AM
Feb-07-22 09:38AM
Feb-01-22 09:15AM
Dec-06-21 11:58AM
Sep-28-21 09:00AM
Sep-10-21 09:00AM
Aug-05-21 10:00AM
Jul-26-21 09:15AM
09:00AM Loading…
Jul-21-21 09:00AM
Jul-14-21 09:00AM
Jul-07-21 09:00AM
Jun-24-21 09:00AM
Jun-14-21 09:00AM
Jun-09-21 09:00AM
05:38AM
May-19-21 09:00AM
May-10-21 09:00AM
Apr-26-21 09:00AM
Apr-01-21 09:00AM
Mar-05-21 09:00AM
Feb-25-21 09:12AM
Feb-12-21 09:00AM
Feb-09-21 09:00AM
Synaptogenix, Inc. is a biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer's disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson's Disease, Traumatic Brain Injury, and Stroke. The company was founded on October 31, 2012 and is headquartered in New York, NY.